1. Understanding How IL-23p19 Inhibitors Work in Psoriasis

2. This program will include a discussion of data some of which has only been presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. The Role of IL-23 in the Psoriasis Disease Cascade

5. The Role of IL-23 in the Psoriasis Disease Cascade (cont)

6. Therapeutic Strategy in Psoriasis -- Difference Between Upstream and Downstream Inhibition

7. IL-23 Inhibitors in Moderate-to-Severe Psoriasis -- Approved and in Latest Development Stages

8. Difference Between Ustekinumab (IL-12/ IL-23p40 Inhibitor) and IL-23p19 Inhibitors

9. Guselkumab vs Adalimumab: VOYAGE-1 and VOYAGE-2

10. Guselkumab vs Secukinumab: ECLIPSE

11. Tildrakizumab vs Etanercept: reSURFACE-1 and reSURFACE-2

12. How Do Guselkumab, Tildrakizumab, and Ustekinumab Compare
How Do Guselkumab, Tildrakizumab, and Ustekinumab Compare? -- Expert Perspective

13. Risankizumab vs Ustekinumab -- ultIMMA & Risankizumab vs Adalimumab -- IMMvent

14. PASI 90/100 as Endpoints -- Expert Perspective

15. Mirikizumab: PASI 90 at Week 16 Phase 2 Study

16. Ranking of IL-23p19 Inhibitors -- Expert Perspective

17. What Are the Differences Between IL-23p19 and IL-17 Inhibitors?

18. IL-23p19 Inhibitors -- Insights on Remission and Disease Modifying Effect

19. IL-23p19 Inhibitors -- Insights on Remission and Disease Modifying Effect (cont)

20. Durability of IL-23p19 Inhibitors

21. Difficult to Treat Psoriasis -- Ixekizumab IXORA-S Study in Nail Psoriasis

22. Difficult to Treat Psoriasis -- Guselkumab NAPSI and f-PGA (VOYAGE-2)

23. Difficult to Treat Psoriasis -- Risankizumab

24. Additional Indications Under Investigation for IL-23p19 Inhibitors

25. PASI 90/PASI 100 and Quality of Life -- What Is the Value for Patients?

26. Experience Using IL-23p19 Inhibitors -- Expert Perspective

27. Concluding Remarks

28. Concluding Remarks (cont)

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)